These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38167245)

  • 1. AZD1775 and anti-PD-1 antibody synergistically sensitize hepatoma to radiotherapy.
    Yin Y; Wang J; Yi J; Zhang K; Yin Z; Jin S; Zheng B
    Chin Med J (Engl); 2024 Jan; 137(2):222-231. PubMed ID: 38167245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
    Yang L; Shen C; Pettit CJ; Li T; Hu AJ; Miller ED; Zhang J; Lin SH; Williams TM
    Clin Cancer Res; 2020 Jul; 26(14):3740-3750. PubMed ID: 32220892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation.
    Wang B; Sun L; Yuan Z; Tao Z
    Med Oncol; 2020 Jul; 37(8):66. PubMed ID: 32696094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
    Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition.
    Patel P; Sun L; Robbins Y; Clavijo PE; Friedman J; Silvin C; Van Waes C; Cook J; Mitchell J; Allen C
    Oncoimmunology; 2019; 8(11):e1638207. PubMed ID: 31646086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the
    Iannuzzi CA; Indovina P; Forte IM; Di Somma S; Malfitano AM; Bruno M; Portella G; Pentimalli F; Giordano A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33020398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair.
    Ford JB; Baturin D; Burleson TM; Van Linden AA; Kim YM; Porter CC
    Oncotarget; 2015 Sep; 6(29):28001-10. PubMed ID: 26334102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer.
    Sand A; Piacsek M; Donohoe DL; Duffin AT; Riddell GT; Sun C; Tang M; Rovin RA; Tjoe JA; Yin J
    Cancer Lett; 2020 Mar; 472():119-131. PubMed ID: 31866466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.
    Brunner A; Suryo Rahmanto A; Johansson H; Franco M; Viiliäinen J; Gazi M; Frings O; Fredlund E; Spruck C; Lehtiö J; Rantala JK; Larsson LG; Sangfelt O
    Elife; 2020 Jul; 9():. PubMed ID: 32628111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk
    Tanaka N; Patel AA; Tang L; Silver NL; Lindemann A; Takahashi H; Jaksik R; Rao X; Kalu NN; Chen TC; Wang J; Frederick MJ; Johnson F; Gleber-Netto FO; Fu S; Kimmel M; Wang J; Hittelman WN; Pickering CR; Myers JN; Osman AA
    Clin Cancer Res; 2017 Nov; 23(21):6541-6554. PubMed ID: 28790110
    [No Abstract]   [Full Text] [Related]  

  • 14. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
    Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
    Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
    Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
    Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
    Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells.
    Moiseeva TN; Qian C; Sugitani N; Osmanbeyoglu HU; Bakkenist CJ
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):23891-23893. PubMed ID: 31712441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
    Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
    Cancer Res Treat; 2020 Jan; 52(1):149-166. PubMed ID: 31291716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer.
    Seo HR; Nam AR; Bang JH; Oh KS; Kim JM; Yoon J; Kim TY; Oh DY
    Cancer Res Treat; 2022 Apr; 54(2):541-553. PubMed ID: 34352995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.